Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC.
Device
Heart failure
Medical therapy
Risk factor
Sex
Women
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
revised:
11
04
2024
received:
05
02
2024
accepted:
29
04
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Despite the progress in the care of individuals with heart failure (HF), important sex disparities in knowledge and management remain, covering all the aspects of the syndrome, from aetiology and pathophysiology to treatment. Important distinctions in phenotypic presentation are widely known, but the mechanisms behind these differences are only partially defined. The impact of sex-specific conditions in the predisposition to HF has gained progressive interest in the HF community. Under-recruitment of women in large randomized clinical trials has continued in the more recent studies despite epidemiological data no longer reporting any substantial difference in the lifetime risk and prognosis between sexes. Target dose of medications and criteria for device eligibility are derived from studies with a large predominance of men, whereas specific information in women is lacking. The present scientific statement encompasses the whole scenario of available evidence on sex-disparities in HF and aims to define the most challenging and urgent residual gaps in the evidence for the scientific and clinical HF communities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–1858. https://doi.org/10.1016/S0140‐6736(18)32279‐7
Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence‐based therapy and survival in heart failure in Sweden 2003‐2012. Eur J Heart Fail 2016;18:503–511. https://doi.org/10.1002/ejhf.496
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland. Eur J Heart Fail 2017;19:1095–1104. https://doi.org/10.1002/ejhf.822
Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996–1004. https://doi.org/10.1001/jamainternmed.2015.0924
Akwo EA, Kabagambe EK, Wang TJ, Harrell FE Jr, Blot WJ, Mumma M, et al. Heart failure incidence and mortality in the Southern Community Cohort Study. Circ Heart Fail 2017;10:e003553. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003553
Tromp J, Ezekowitz JA, Ouwerkerk W, Chandramouli C, Yiu KH, Angermann CE, et al. Global variations according to sex in patients hospitalized for heart failure in the REPORT‐HF registry. JACC Heart Fail 2023;11:1262–1271. https://doi.org/10.1016/j.jchf.2023.06.028
Lainscak M, Milinkovic I, Polovina M, Crespo‐Leiro MG, Lund LH, Anker SD, et al.; European Society of Cardiology Heart Failure Long‐Term Registry Investigators Group. Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: An analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry. Eur J Heart Fail 2020;22:92–102. https://doi.org/10.1002/ejhf.1645
Ramirez FD, Motazedian P, Jung RG, Di Santo P, MacDonald Z, Simard T, et al. Sex bias is increasingly prevalent in preclinical cardiovascular research: Implications for translational medicine and health equity for women: A systematic assessment of leading cardiovascular journals over a 10‐year period. Circulation 2017;135:625–626. https://doi.org/10.1161/CIRCULATIONAHA.116.026668
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412. https://doi.org/10.1371/journal.pbio.1000412
Persson PB. Good publication practice in physiology 2017: Current revisions of the recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. Acta Physiol (Oxf) 2017;221:283–284. https://doi.org/10.1111/apha.12984
Perrino C, Ferdinandy P, Bøtker H, Brundel BJJM, Collins P, Davidson SM, et al. Improving translational research in sex‐specific effects of comorbidities and risk factors in ischemic heart disease and cardioprotection: Position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res 2021;21:367–385. https://doi.org/10.1093/cvr/cvaa155
Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen‐responsive cells in culture. Proc Natl Acad Sci U S A 1986;83:2496–2500. https://doi.org/10.1073/pnas.83.8.2496
Arnold AP. Conceptual frameworks and mouse models for studying sex differences in physiology and disease: Why compensation changes the game. Exp Neurol 2014;259:2–9. https://doi.org/10.1016/j.expneurol.2014.01.021
Lloyd‐Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al.; Framingham Heart Study. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002;106:3068–3072. https://doi.org/10.1161/01.cir.0000039105.49749.6f
Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al.; EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: The EPICA study. Eur J Heart Fail 2002;4:531–539. https://doi.org/10.1016/s1388‐9842(02)00034‐x
Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: A population‐based study of 4 million individuals. Lancet 2018;391:572–580. https://doi.org/10.1016/S0140‐6736(17)32520‐5
Anguita Sanchez M, Crespo Leiro MG, de Teresa Galvan E, Jimenez Navarro M, Alonso‐Pulpon L, Muniz Garcia J; PRICE Study Investigators. Prevalence of heart failure in the Spanish general population aged over 45 years. Rev Esp Cardiol 2008;61:1041–1049. https://doi.org/10.1016/s1885‐5857(09)60007‐4
Paren P, Schaufelberger M, Bjorck L, Lappas G, Fu M, Rosengren A. Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail 2014;16:737–742. https://doi.org/10.1002/ejhf.109
Zarrinkoub R, Wettermark B, Wandell P, Mejhert M, Szulkin R, Ljunggren G, et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013;15:995–1002. https://doi.org/10.1093/eurjhf/hft064
Odegaard KM, Hallen J, Lirhus SS, Melberg HO, Halvorsen S. Incidence, prevalence, and mortality of heart failure: A nationwide registry study from 2013 to 2016. ESC Heart Fail 2020;7:1917–1926. https://doi.org/10.1002/ehf2.12773
Piccinni C, Antonazzo IC, Simonetti M, Mennuni MG, Parretti D, Cricelli C, et al. The burden of chronic heart failure in primary care in Italy. High Blood Press Cardiovasc Prev 2017;24:171–178. https://doi.org/10.1007/s40292‐017‐0193‐4
McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: Focus on acute and chronic heart failure. Can J Cardiol 2013;29:168–181. https://doi.org/10.1016/j.cjca.2012.10.007
Seferovic PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinkovic I, et al.; National Heart Failure Societies of the ESC member countries. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021;23:906–914. https://doi.org/10.1002/ejhf.2143
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.; Writing Group Members, American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics‐2016 update: A report from the American Heart Association. Circulation 2016;133:e38–e360. https://doi.org/10.1161/CIR.0000000000000350
Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, et al. Sex differences in new‐onset heart failure. Clin Res Cardiol 2015;104:342–350. https://doi.org/10.1007/s00392‐014‐0788‐x
Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, et al. 20‐year trends in cause‐specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: A population‐based study. Lancet Public Health 2019;4:e406–e420. https://doi.org/10.1016/S2468‐2667(19)30108‐2
Chang PP, Wruck LM, Shahar E, Rossi JS, Loehr LR, Russell SD, et al. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005‐2014): ARIC study community surveillance. Circulation 2018;138:12–24. https://doi.org/10.1161/CIRCULATIONAHA.117.027551
Goldberg RJ, Spencer FA, Farmer C, Meyer TE, Pezzella S. Incidence and hospital death rates associated with heart failure: A community‐wide perspective. Am J Med 2005;118:728–734. https://doi.org/10.1016/j.amjmed.2005.04.013
Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, et al. Predicting heart failure with preserved and reduced ejection fraction: The international collaboration on heart failure subtypes. Circ Heart Fail 2016;9:e003116. https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116
Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex‐based differences in heart failure across the ejection fraction spectrum: Phenotyping, and prognostic and therapeutic implications. JACC Heart Fail 2019;7:505–515. https://doi.org/10.1016/j.jchf.2019.03.011
Ibrahim R, Shahid M, Tan MC, Martyn T, Lee JZ, William P. Exploring heart failure mortality trends and disparities in women: A retrospective cohort analysis. Am J Cardiol 2023;209:42–51. https://doi.org/10.1016/j.amjcard.2023.09.087
Biondi‐Zoccai GG, Abate A, Bussani R, Camilot D, Giorgio FD, Marino MP, et al. Reduced post‐infarction myocardial apoptosis in women: A clue to their different clinical course? Heart 2005;91:99–101. https://doi.org/10.1136/hrt.2003.018754
DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, et al. Heart failure subtypes and cardiomyopathies in women. Circ Res 2022;130:436–454. https://doi.org/10.1161/CIRCRESAHA.121.319900
Dunlay SM, Roger VL. Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep 2012;9:267–276. https://doi.org/10.1007/s11897‐012‐0107‐7
Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen NB, et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation 2018;137:1814–1823. https://doi.org/10.1161/CIRCULATIONAHA.117.031622
Breathett K, Leng I, Foraker RE, Abraham WT, Coker L, Whitfield KE, et al. Risk factor burden, heart failure, and survival in women of different ethnic groups: Insights from the Women's Health Initiative. Circ Heart Fail 2018;11:e004642. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004642
Nielsen RR, Anker N, Stodkilde‐Jorgensen N, Thrane PG, Hansen MK, Pryds K, et al. Impact of coronary artery disease in women with newly diagnosed heart failure and reduced ejection fraction. JACC Heart Fail 2023;11:1653–1663. https://doi.org/10.1016/j.jchf.2023.07.013
Eaton CB, Pettinger M, Rossouw J, Martin LW, Foraker R, Quddus A, et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail 2016;9:e002883. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002883
Chandra A, Skali H, Claggett B, Solomon SD, Rossi JS, Russell SD, et al. Race‐ and gender‐based differences in cardiac structure and function and risk of heart failure. J Am Coll Cardiol 2022;79:355–368. https://doi.org/10.1016/j.jacc.2021.11.024
Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, et al. Predictors of new‐onset heart failure: Differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013;6:279–286. https://doi.org/10.1161/CIRCHEARTFAILURE.112.972828
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974;34:29–34. https://doi.org/10.1016/0002‐9149(74)90089‐7
Seghieri C, Francesconi P, Cipriani S, Rapana M, Anichini R, Franconi F, et al. Gender effect on the relation between diabetes and hospitalization for heart failure. Exp Clin Endocrinol Diabetes 2012;120:51–55. https://doi.org/10.1055/s‐0031‐1284377
Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85–89. https://doi.org/10.1016/0002‐9149(91)90716‐x
Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, et al.; PARAMOUNT Investigators. Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014;16:535–542. https://doi.org/10.1002/ejhf.67
Shim CY, Park S, Choi D, Yang WI, Cho IJ, Choi EY, et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol 2011;57:1226–1233. https://doi.org/10.1016/j.jacc.2010.09.067
Sciatti E, Coccia MG, Magnano R, Aakash G, Limonta R, Diep B, et al. Heart failure preserved ejection fraction in women: Insights learned from imaging. Heart Fail Clin 2023;19:461–473. https://doi.org/10.1016/j.hfc.2023.06.001
Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (I‐PRESERVE) trial. Circ Heart Fail 2012;5:571–578. https://doi.org/10.1161/CIRCHEARTFAILURE.112.970061
Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701–709. https://doi.org/10.1016/j.jchf.2018.05.018
Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271. https://doi.org/10.1016/j.jacc.2013.02.092
Canto ED, van Deursen L, Hoek AG, Elders PJM, den Ruijter HM, van der Velden J, et al. Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: The Hoorn Diabetes Care System Cohort. Cardiovasc Diabetol 2023;22:234. https://doi.org/10.1186/s12933‐023‐01935‐z
Davis MR, Lee CS, Corcoran A, Gupta N, Uchmanowicz I, Denfeld QE. Gender differences in the prevalence of frailty in heart failure: A systematic review and meta‐analysis. Int J Cardiol 2021;333:133–140. https://doi.org/10.1016/j.ijcard.2021.02.062
Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: A hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020;22:1551–1567. https://doi.org/10.1002/ejhf.1902
Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype‐specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 2016;134:73–90. https://doi.org/10.1161/CIRCULATIONAHA.116.021884
Ravera A, Santema BT, de Boer RA, Anker SD, Samani NJ, Lang CC, et al. Distinct pathophysiological pathways in women and men with heart failure. Eur J Heart Fail 2022;24:1532–1544. https://doi.org/10.1002/ejhf.2534
Packer M, Kitzman DW. Obesity‐related heart failure with a preserved ejection fraction: The mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium‐glucose cotransporter‐2. JACC Heart Fail 2018;6:633–639. https://doi.org/10.1016/j.jchf.2018.01.009
Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. Eur J Heart Fail 2022;24:2355–2363. https://doi.org/10.1002/ejhf.2646
Aimo A, Panichella G, Garofalo M, Gasparini S, Arzilli C, Castiglione V, et al. Sex differences in transthyretin cardiac amyloidosis. Heart Fail Rev 2024;29:321–330. https://doi.org/10.1007/s10741‐023‐10339‐w
Argiro A, Ho C, Day SM, van der Velden J, Cerbai E, Saberi S, et al. Sex‐related differences in genetic cardiomyopathies. J Am Heart Assoc 2022;11:e024947. https://doi.org/10.1161/JAHA.121.024947
Regensteiner JG, Golden S, Huebschmann AG, Barrett‐Connor E, Chang AY, Chyun D, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, Council on Hypertension. Sex differences in the cardiovascular consequences of diabetes mellitus: A scientific statement from the American Heart Association. Circulation 2015;132:2424–2447. https://doi.org/10.1161/CIR.0000000000000343
Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state‐of‐the‐art review. J Am Coll Cardiol 2020;75:207–221. https://doi.org/10.1016/j.jacc.2019.11.014
Williams D, Stout MJ, Rosenbloom JI, Olsen MA, Joynt Maddox KE, Deych E, et al. Preeclampsia predicts risk of hospitalization for heart failure with preserved ejection fraction. J Am Coll Cardiol 2021;78:2281–2290. https://doi.org/10.1016/j.jacc.2021.09.1360
Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker‐Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:827–843. https://doi.org/10.1002/ejhf.1493
Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker‐Kleiner D. Peripartum cardiomyopathy: From genetics to management. Eur Heart J 2021;42:3094–3102. https://doi.org/10.1093/eurheartj/ehab458
Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 2013;38:7–46. https://doi.org/10.1016/j.cpcardiol.2012.07.003
Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009;6:532–542. https://doi.org/10.1038/nrcardio.2009.105
Barton M, Meyer MR. Heart failure with preserved ejection fraction in women: New clues to causes and treatment. JACC Basic Transl Sci 2020;5:296–299. https://doi.org/10.1016/j.jacbts.2020.02.001
Komukai K, Mochizuki S, Yoshimura M. Gender and the renin‐angiotensin‐aldosterone system. Fundam Clin Pharmacol 2010;24:687–698. https://doi.org/10.1111/j.1472‐8206.2010.00854.x
Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011;109:687–696. https://doi.org/10.1161/CIRCRESAHA.110.236687
Sickinghe AA, Korporaal SJA, den Ruijter HM, Kessler EL. Estrogen contributions to microvascular dysfunction evolving to heart failure with preserved ejection fraction. Front Endocrinol (Lausanne) 2019;10:442. https://doi.org/10.3389/fendo.2019.00442
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626–638. https://doi.org/10.1038/nri.2016.90
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al.; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow‐up (HERS II). JAMA 2002;288:49–57. https://doi.org/10.1001/jama.288.1.49
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333. https://doi.org/10.1001/jama.288.3.321
Sotomi Y, Hikoso S, Nakatani D, Mizuno H, Okada K, Dohi T, et al.; PURSUIT‐HFpEF Investigators. Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc 2021;10:e018574. https://doi.org/10.1161/JAHA.120.018574
Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: A detailed invasive hemodynamic and echocardiographic analysis. JACC Heart Fail 2019;7:239–249. https://doi.org/10.1016/j.jchf.2019.01.004
Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010;56:845–854. https://doi.org/10.1016/j.jacc.2010.03.077
Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev 2021;30:200330. https://doi.org/10.1183/16000617.0330‐2020
Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J 2014;43:523–530. https://doi.org/10.1183/09031936.00027613
Kitzman DW, Nicklas BJ. Pivotal role of excess intra‐abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018;6:1008–1010. https://doi.org/10.1016/j.jchf.2018.08.007
Kok HS, van Asselt KM, van der Schouw YT, van der Tweel I, Peeters PH, Wilson PW, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006;47:1976–1983. https://doi.org/10.1016/j.jacc.2005.12.066
Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy‐associated cardiovascular disease. Nat Rev Clin Oncol 2016;13:172–184. https://doi.org/10.1038/nrclinonc.2015.171
Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:809–816. https://doi.org/10.1016/j.jacc.2013.10.061
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging 2020;13:198–210. https://doi.org/10.1016/j.jcmg.2019.07.018
Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al‐Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta‐analysis. Eur J Heart Fail 2020;22:350–361. https://doi.org/10.1002/ejhf.1631
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Civelli M, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2016;133:1981–1988. https://doi.org/10.1161/CIRCULATIONAHA.115.018780
Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, et al. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc 2020;9:e014708. https://doi.org/10.1161/JAHA.119.014708
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol 2014;63:2751–2768. https://doi.org/10.1016/j.jacc.2014.01.073
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy‐induced cardiotoxicity: A systematic review and meta‐analysis. JAMA Cardiol 2019;4:1007–1018. https://doi.org/10.1001/jamacardio.2019.2952
Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol 2019;1:68–79. https://doi.org/10.1016/j.jaccao.2019.08.003
Vejpongsa P, Yeh ET. Prevention of anthracycline‐induced cardiotoxicity: Challenges and opportunities. J Am Coll Cardiol 2014;64:938–945. https://doi.org/10.1016/j.jacc.2014.06.1167
Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A. Prevention of anthracycline‐induced cardiotoxicity: A systematic review and meta‐analysis. Intern Emerg Med 2021;16:477–486. https://doi.org/10.1007/s11739‐020‐02508‐8
Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta‐blockers in chemotherapy‐induced cardiotoxicity‐a systematic review and meta‐analysis of carvedilol. Heart Fail Rev 2019;24:325–333. https://doi.org/10.1007/s10741‐018‐9755‐3
Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 2019;1:54–65. https://doi.org/10.1016/j.jaccao.2019.08.006
Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012;60:2504–2512. https://doi.org/10.1016/j.jacc.2012.07.068
Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al.; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012;104:1293–1305. https://doi.org/10.1093/jnci/djs317
Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for anthracycline‐associated cardiac dysfunction: The STOP‐CA randomized clinical trial. JAMA 2023;330:528–536. https://doi.org/10.1001/jama.2023.11887
Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 2016;133:537–541. https://doi.org/10.1161/CIRCULATIONAHA.115.012519
Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N‐terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745–751. https://doi.org/10.1136/heart.89.7.745
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976–982. https://doi.org/10.1016/s0735‐1097(02)02059‐4
Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254–258. https://doi.org/10.1016/s0002‐9149(02)02464‐5
Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A, et al. Long‐term pattern of brain natriuretic peptide and N‐terminal pro brain natriuretic peptide and its determinants in the general population: Contribution of age, gender, and cardiac and extra‐cardiac factors. Eur J Heart Fail 2013;15:859–867. https://doi.org/10.1093/eurjhf/hft048
Cediel G, Codina P, Spitaleri G, Domingo M, Santiago‐Vacas E, Lupon J, et al. Gender‐related differences in heart failure biomarkers. Front Cardiovasc Med 2020;7:617705. https://doi.org/10.3389/fcvm.2020.617705
Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton‐Cheh C, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol 2011;58:618–626. https://doi.org/10.1016/j.jacc.2011.03.042
Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: Observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49:109–116. https://doi.org/10.1016/j.jacc.2006.10.040
Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, et al. Sex‐specific associations of obesity and N‐terminal pro‐B‐type natriuretic peptide levels in the general population. Eur J Heart Fail 2018;20:1205–1214. https://doi.org/10.1002/ejhf.1209
Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: Results from the BACH multinational study. Eur J Heart Fail 2012;14:22–31. https://doi.org/10.1093/eurjhf/hfr157
Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al.; BNP Multinational Study Investigators. Impact of age, race, and sex on the ability of B‐type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:1078–1084. https://doi.org/10.1016/j.ahj.2004.01.013
Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of amino‐terminal pro‐brain natriuretic peptide testing in dyspneic subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006;12:452–457. https://doi.org/10.1016/j.cardfail.2006.04.005
Hsich EM, Grau‐Sepulveda MV, Hernandez AF, Eapen ZJ, Xian Y, Schwamm LH, et al. Relationship between sex, ejection fraction, and B‐type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: Findings from the Get With The Guideline‐Heart Failure Registry. Am Heart J 2013;166:1063–1071.e3. https://doi.org/10.1016/j.ahj.2013.08.029
Vallabhajosyula S, Verghese D, Desai VK, Sundaragiri PR, Miller VM. Sex differences in acute cardiovascular care: A review and needs assessment. Cardiovasc Res 2022;118:667–685. https://doi.org/10.1093/cvr/cvab063
Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al.; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209–216. https://doi.org/10.1016/j.ahj.2004.08.005
Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ; National Heart Failure Audit Team for England and Wales. The national heart failure audit for England and Wales 2008‐2009. Heart 2011;97:876–886. https://doi.org/10.1136/hrt.2010.209171
Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006;27:2725–2736. https://doi.org/10.1093/eurheartj/ehl193
Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM‐HF). Intensive Care Med 2011;37:619–626. https://doi.org/10.1007/s00134‐010‐2113
Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929–938. https://doi.org/10.1056/NEJMoa1406761
Keshvani N, Shah S, Ayodele I, Chiswell K, Alhanti B, Allen LA, et al. Sex differences in long‐term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines‐Heart Failure registry. Eur J Heart Fail 2023;25:1544–1554. https://doi.org/10.1002/ejhf.3003
Vallabhajosyula S, Ya'Qoub L, Singh M, Bell MR, Gulati R, Cheungpasitporn W, et al. Sex disparities in the management and outcomes of cardiogenic shock complicating acute myocardial infarction in the young. Circ Heart Fail 2020;13:e007154. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007154
Elgendy IY, Wegermann ZK, Li S, Mahtta D, Grau‐Sepulveda M, Smilowitz NR, et al. Sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock. JACC Cardiovasc Interv 2022;15:642–652. https://doi.org/10.1016/j.jcin.2021.12.033
Yan I, Schrage B, Weimann J, Dabboura S, Hilal R, Beer BN, et al. Sex differences in patients with cardiogenic shock. ESC Heart Fail 2021;8:1775–1783. https://doi.org/10.1002/ehf2.13303
Wang AS, Nemeth S, Kurlansky P, Brodie D, Takayama H, Naka Y, et al. Sex differences in patients with cardiogenic shock requiring extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2022;164:960–969.e6. https://doi.org/10.1016/j.jtcvs.2020.12.044
Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, et al.; ATOMIC‐AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC‐AHF study. J Am Coll Cardiol 2016;67:1444–1455. https://doi.org/10.1016/j.jacc.2016.01.031
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al.; REVIVE Heart Failure Study Group. Effect of levosimendan on the short‐term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103–111. https://doi.org/10.1016/j.jchf.2012.12.004
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 2021;385:516–525. https://doi.org/10.1056/NEJMoa2026845
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 2007;297:1319–1331. https://doi.org/10.1001/jama.297.12.1319
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz‐Zagrosek V, et al.; ASIAN‐HF Investigators. Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study. Lancet 2019;394:1254–1263. https://doi.org/10.1016/S0140‐6736(19)31792‐1
Ferreira JP, Konstam MA, McMurray JJV, Butler J, Girerd N, Rossignol P, et al. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: The HEAAL trial. Eur J Heart Fail 2021;23:1477–1484. https://doi.org/10.1002/ejhf.2255
Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female‐specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585–1595. https://doi.org/10.1093/eurheartj/ehi397
Eugene AR. Gender based dosing of metoprolol in the elderly using population pharmacokinetic modeling and simulations. Int J Clin Pharmacol Toxicol 2016;5:209–215. https://doi.org/10.19070/2167‐910X‐1600035
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48:143–157. https://doi.org/10.2165/00003088‐200948030‐00001
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–878. https://doi.org/10.1001/jama.289.7.871
Rathore SS, Wang Y, Krumholz HM. Sex‐based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403–1411. https://doi.org/10.1056/NEJMoa021266
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533. https://doi.org/10.1056/NEJM199702203360801
Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499–523. https://doi.org/10.1146/annurev.pharmtox.44.101802.121453
Oertelt‐Prigione S, Regitz‐Zagrosek V. Gender aspects in cardiovascular pharmacology. J Cardiovasc Transl Res 2009;2:258–266. https://doi.org/10.1007/s12265‐009‐9114‐9
Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, et al. Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J 2015;36:2677–2680. https://doi.org/10.1093/eurheartj/ehv161
Schroeder M, Lim YMF, Savarese G, Suzart‐Woischnik K, Baudier C, Dyszynski T, et al. Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction. Eur J Heart Fail 2023;25:912–921. https://doi.org/10.1002/ejhf.2868
Hsich EM, Pina IL. Heart failure in women: A need for prospective data. J Am Coll Cardiol 2009;54:491–498. https://doi.org/10.1016/j.jacc.2009.02.066
Dewan P, Rorth R, Jhund PS, Shen L, Raparelli V, Petrie MC, et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol 2019;73:29–40. https://doi.org/10.1016/j.jacc.2018.09.081
Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM. Under‐representation of elderly and women in clinical trials. Int J Cardiol 2017;232:216–221.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol Heart Failure study Group. N Engl J Med 1996;334:1349–1355. https://doi.org/10.1016/j.ijcard.2017.01.018
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435. https://doi.org/10.1056/NEJM198706043162301
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992;327:669–677. https://doi.org/10.1056/NEJM199209033271001
SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327(10):685–691. https://doi.org/10.1056/NEJM199209033271003
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin‐converting enzyme inhibitors and beta‐blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta‐analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–1538. https://doi.org/10.1016/s0735‐1097(03)00262‐6
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al.; Beta‐Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta‐analysis. BMJ 2016;353:i1855. https://doi.org/10.1136/bmj.i1855
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–225. https://doi.org/10.1093/eurheartj/ehi115
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821–828. https://doi.org/10.1016/0140‐6736(93)92693‐N
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000;342(3):145–153.
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747–752. https://doi.org/10.1016/s0140‐6736(97)01187‐2
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675. https://doi.org/10.1056/NEJMoa010713
Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752–760. https://doi.org/10.1016/s0140‐6736(02)09895‐1
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906. https://doi.org/10.1056/NEJMoa032292
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM‐Overall programme. Lancet 2003;362:759–766. https://doi.org/10.1016/s0140‐6736(03)14282‐1
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717. https://doi.org/10.1056/NEJM199909023411001
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS‐HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
Ibrahim NE, Pina IL, Camacho A, Bapat D, Felker GM, Maisel AS, et al.; Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE‐HF) Study Investigators. Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Eur J Heart Fail 2020;22:2018–2025. https://doi.org/10.1002/ejhf.2005
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al.; DAPA‐HF Trial Committees and Investigators. Dapagliflozin in patients with Heart Failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Packer M, Butler J, Zannad F, Pocock SJ, Filippatos G, Ferreira JP, et al.; EMPEROR Study Group. Empagliflozin and major renal outcomes in heart failure. N Engl J Med 2021;385:1531–1533. https://doi.org/10.1056/NEJMc2112411
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883–1893. https://doi.org/10.1056/NEJMoa1915928
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al.; GALACTIC‐HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 2021;384:105–116. https://doi.org/10.1056/NEJMoa2025797
Lam CSP, Pina IL, Zheng Y, Bonderman D, Pouleur AC, Saldarriaga C, et al.; VICTORIA Study Group. Age, sex, and outcomes in heart failure with reduced EF: Insights from the VICTORIA trial. JACC Heart Fail 2023;11:1246–1257. https://doi.org/10.1016/j.jchf.2023.06.020
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med 2021;27:1954–1960. https://doi.org/10.1038/s41591‐021‐01536‐x
Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: A secondary analysis of TOPCAT trial. JACC Heart Fail 2019;7:228–238. https://doi.org/10.1016/j.jchf.2019.01.003
Rossello X, Ferreira JP, Pocock SJ, McMurray JJV, Solomon SD, Lam CSP, et al. Sex differences in mineralocorticoid receptor antagonist trials: A pooled analysis of three large clinical trials. Eur J Heart Fail 2020;22:834–844. https://doi.org/10.1002/ejhf.1740
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril‐valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON‐HF. Circulation 2020;141:338–351. https://doi.org/10.1161/CIRCULATIONAHA.119.044491
Novella S, Perez‐Cremades D, Mompeon A, Hermenegildo C. Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women. J Physiol 2019;597:4873–4886. https://doi.org/10.1113/JP278063
Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi E, et al. Effects of empagliflozin in women and men with heart failure and preserved ejection fraction. Circulation 2022;146:1046–1055. https://doi.org/10.1161/CIRCULATIONAHA.122.059755
Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, et al. Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA‐HF and DELIVER. Circulation 2023;147:624–634. https://doi.org/10.1161/CIRCULATIONAHA.122.062832
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al.; AFFIRM‐AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double‐blind, randomised, controlled trial. Lancet 2020;396:1895–1904. https://doi.org/10.1016/S0140‐6736(20)32339‐4
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al.; HEART‐FID Investigators. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 2023;389:975–986. https://doi.org/10.1056/NEJMoa2304968
Cohen‐Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 2014;16:984–991. https://doi.org/10.1002/ejhf.139
Cerlinskaite‐Bajore K, Lam CSP, Sliwa K, Adamo M, Ter Maaten JM, Leopold V, et al. Sex‐specific analysis of the rapid up‐titration of guideline‐directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG‐HF trial. Eur J Heart Fail 2023;25:1156–1165. https://doi.org/10.1002/ejhf.2882
Hsich EM. Sex differences in advanced heart failure therapies. Circulation 2019;139:1080–1093. https://doi.org/10.1161/CIRCULATIONAHA.118.037369
Chatterjee NA, Borgquist R, Chang Y, Lewey J, Jackson VA, Singh JP, et al. Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter‐defibrillator. Eur Heart J 2017;38:1485–1494. https://doi.org/10.1093/eurheartj/ehw598
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP‐HF registry. J Am Coll Cardiol 2018;72:351–366. https://doi.org/10.1016/j.jacc.2018.04.070
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al.; American Heart Association Council on E, Prevention Statistics C, Stroke Statistics S. Heart disease and stroke statistics‐2019 update: A report from the American Heart Association. Circulation 2019;139:e56–e528. https://doi.org/10.1161/CIR.0000000000000659
Bots SH, den Ruijter HM. Recommended heart failure medications and adverse drug reactions in women. Circulation 2019;139:1469–1471. https://doi.org/10.1161/CIRCULATIONAHA.118.037585
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al.; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant 2013;32:157–187. https://doi.org/10.1016/j.healun.2012.09.013
Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlstrom U, et al. Real‐world use of sodium‐glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure registry. Eur J Heart Fail 2023;25:1648–1658. https://doi.org/10.1002/ejhf.2971
Curtis LH, Al‐Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter‐defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007;298:1517–1524. https://doi.org/10.1001/jama.298.13.1517
Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al.; EU‐CERT‐ICD Investigators. Sex differences in outcomes of primary prevention implantable cardioverter‐defibrillator therapy: Combined registry data from eleven European countries. Europace 2018;20:963–970. https://doi.org/10.1093/europace/eux176
Hess PL, Hernandez AF, Bhatt DL, Hellkamp AS, Yancy CW, Schwamm LH, et al. Sex and race/ethnicity differences in implantable cardioverter‐defibrillator counseling and use among patients hospitalized with heart failure: Findings from the Get With The Guidelines‐Heart Failure Program. Circulation 2016;134:517–526. https://doi.org/10.1161/CIRCULATIONAHA.115.021048
Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, et al.; National Cardiovascular Data Registry. Gender differences in procedure‐related adverse events in patients receiving implantable cardioverter‐defibrillator therapy. Circulation 2009;119:1078–1084. https://doi.org/10.1161/CIRCULATIONAHA.108.793463
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883. https://doi.org/10.1056/NEJMoa013474
Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al.; AMIOVIRT Investigators. Amiodarone versus implantable cardioverter‐defibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol 2003;41:1707–1712. https://doi.org/10.1016/s0735‐1097(03)00297‐3
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al.; Defibrillators in Non‐Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151–2158. https://doi.org/10.1056/NEJMoa033088
Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–2488. https://doi.org/10.1056/NEJMoa041489
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT) Investigators. Amiodarone or an implantable cardioverter‐defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237. https://doi.org/10.1056/NEJMoa043399
Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al.; IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427–1436. https://doi.org/10.1056/NEJMoa0901889
Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al.; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221–1230. https://doi.org/10.1056/NEJMoa1608029
Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al.; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873–880. https://doi.org/10.1056/NEJM200103223441202
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al.; MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853. https://doi.org/10.1056/NEJMoa013168
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al.; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. JAMA 2003;289:2685–2694. https://doi.org/10.1001/jama.289.20.2685
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150. https://doi.org/10.1056/NEJMoa032423
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.; Cardiac Resynchronization‐Heart Failure (CARE‐HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549. https://doi.org/10.1056/NEJMoa050496
Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834–1843. https://doi.org/10.1016/j.jacc.2008.08.027
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.; MADIT‐CRT Trial Investigators. Cardiac‐resynchronization therapy for the prevention of heart‐failure events. N Engl J Med 2009;361:1329–1338. https://doi.org/10.1056/NEJMoa0906431
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al.; Resynchronization‐Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac‐resynchronization therapy for mild‐to‐moderate heart failure. N Engl J Med 2010;363:2385–2395. https://doi.org/10.1056/NEJMoa1009540
Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD, et al. Primary results from the SmartDelay determined AV optimization: A comparison to other AV delay methods used in cardiac resynchronization therapy (SMART‐AV) trial: A randomized trial comparing empirical, echocardiography‐guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660–2668. https://doi.org/10.1161/CIRCULATIONAHA.110.992552
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882–1890. https://doi.org/10.1056/NEJM199912163412503
Conen D, Arendacka B, Rover C, Bergau L, Munoz P, Wijers S, et al. Gender differences in appropriate shocks and mortality among patients with primary prophylactic implantable cardioverter‐defibrillators: Systematic review and meta‐analysis. PLoS One 2016;11:e0162756. https://doi.org/10.1371/journal.pone.0162756
Albert CM, Quigg R, Saba S, Estes NA 3rd, Shaechter A, Subacius H, et al.; DEFINITE Investigators. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J 2008;156:367–372. https://doi.org/10.1016/j.ahj.2008.02.026
Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: A systematic review and meta‐analysis. Heart Rhythm 2010;7:876–882. https://doi.org/10.1016/j.hrthm.2010.03.042
Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, et al. Effectiveness of implantable cardioverter‐defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: A meta‐analysis of randomized controlled trials. Arch Intern Med 2009;169:1500–1506. https://doi.org/10.1001/archinternmed.2009.255
Barra S, Providencia R, Boveda S, Narayanan K, Virdee M, Marijon E, et al. Do women benefit equally as men from the primary prevention implantable cardioverter‐defibrillator? Europace 2018;20:897–901. https://doi.org/10.1093/europace/eux203
Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, et al. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter‐defibrillator. Circulation 2012;126:2402–2407. https://doi.org/10.1161/CIRCULATIONAHA.111.069245
Saxena S, Goldenberg I, McNitt S, Hsich E, Kutyifa V, Bragazzi NL, et al. Sex differences in the risk of first and recurrent ventricular tachyarrhythmias among patients receiving an implantable cardioverter‐defibrillator for primary prevention. JAMA Netw Open 2022;5:e2217153. https://doi.org/10.1001/jamanetworkopen.2022.17153
Morgan H, Sinha A, McEntegart M, Hardman SM, Perera D. Evaluation of the causes of sex disparity in heart failure trials. Heart 2022;108:1547–1552. https://doi.org/10.1136/heartjnl‐2021‐320696
Butt JH, Yafasova A, Elming MB, Dixen U, Nielsen JC, Haarbo J, et al. Efficacy of implantable cardioverter defibrillator in nonischemic systolic heart failure according to sex: Extended follow‐up study of the DANISH trial. Circ Heart Fail 2022;15:e009669. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009669
Tadros R, Ton AT, Fiset C, Nattel S. Sex differences in cardiac electrophysiology and clinical arrhythmias: Epidemiology, therapeutics, and mechanisms. Can J Cardiol 2014;30:783–792. https://doi.org/10.1016/j.cjca.2014.03.032
Chimura M, Kiuchi K, Okajima K, Shimane A, Sawada T, Onishi T, et al. Distribution of ventricular fibrosis associated with life‐threatening ventricular tachyarrhythmias in patients with nonischemic dilated cardiomyopathy. J Cardiovasc Electrophysiol 2015;26:1239–1246. https://doi.org/10.1111/jce.12767
Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–1940. https://doi.org/10.1056/NEJM199612263352601
Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O'Callaghan KM, Carpenter JL, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta‐analysis of patient‐level data. JAMA Intern Med 2014;174:1340–1348. https://doi.org/10.1001/jamainternmed.2014.2717
Beela AS, Duchenne J, Petrescu A, Unlu S, Penicka M, Aakhus S, et al. Sex‐specific difference in outcome after cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging 2019;20:504–511. https://doi.org/10.1093/ehjci/jey231
Varma N, Manne M, Nguyen D, He J, Niebauer M, Tchou P. Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB. Heart Rhythm 2014;11:1139–1147. https://doi.org/10.1016/j.hrthm.2014.04.001
Dewidar O, Dawit H, Barbeau V, Birnie D, Welch V, Wells GA. Sex differences in implantation and outcomes of cardiac resynchronization therapy in real‐world settings: A systematic review of cohort studies. CJC Open 2022;4:75–84. https://doi.org/10.1016/j.cjco.2021.09.003
Linde C, Cleland JGF, Gold MR, Claude Daubert J, Tang ASL, Young JB, et al. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: An individual‐patient data meta‐analysis. Eur J Heart Fail 2018;20:780–791. https://doi.org/10.1002/ejhf.1133
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427–3520. https://doi.org/10.1093/eurheartj/ehab364
Obadia JF, Messika‐Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al.; MITRA‐FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297–2306. https://doi.org/10.1056/NEJMoa1805374
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.; COAPT Investigators. Transcatheter mitral‐valve repair in patients with heart failure. N Engl J Med 2018;379:2307–2318. https://doi.org/10.1056/NEJMoa1806640
Kosmidou I, Lindenfeld J, Abraham WT, Rinaldi MJ, Kapadia SR, Rajagopal V, et al. Sex‐specific outcomes of transcatheter mitral‐valve repair and medical therapy for mitral regurgitation in heart failure. JACC Heart Fail 2021;9:674–683. https://doi.org/10.1016/j.jchf.2021.04.011
Park SD, Orban M, Karam N, Lubos E, Kalbacher D, Braun D, et al.; EuroSMR Investigators. Sex‐related clinical characteristics and outcomes of patients undergoing transcatheter edge‐to‐edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv 2021;14:819–827. https://doi.org/10.1016/j.jcin.2020.12.042
Fengler K, Fuernau G, Desch S, Eitel I, Neumann FJ, Olbrich HG, et al. Gender differences in patients with cardiogenic shock complicating myocardial infarction: A substudy of the IABP‐SHOCK II‐trial. Clin Res Cardiol 2015;104:71–78. https://doi.org/10.1007/s00392‐014‐0767‐2
Vallabhajosyula S, Dunlay SM, Barsness GW, Miller PE, Cheungpasitporn W, Stulak JM, et al. Sex disparities in the use and outcomes of temporary mechanical circulatory support for acute myocardial infarction‐cardiogenic shock. CJC Open 2020;2:462–472. https://doi.org/10.1016/j.cjco.2020.06.001
Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019;139:1249–1258. https://doi.org/10.1161/CIRCULATIONAHA.118.036614
Joseph SM, Brisco MA, Colvin M, Grady KL, Walsh MN, Cook JL; genVAD Working Group. Women with cardiogenic shock derive greater benefit from early mechanical circulatory support: An update from the cVAD Registry. J Interv Cardiol 2016;29:248–256. https://doi.org/10.1111/joic.12298
Zeymer U, Freund A, Hochadel M, Ostadal P, Belohlavek J, Rokyta R, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct‐related cardiogenic shock: An individual patient data meta‐analysis of randomised trials. Lancet 2023;402:1338–1346. https://doi.org/10.1016/S0140‐6736(23)01607‐0
Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al.; ECLS‐SHOCK Investigators. Extracorporeal life support in infarct‐related cardiogenic shock. N Engl J Med 2023;389:1286–1297. https://doi.org/10.1056/NEJMoa2307227
Elkayam U, Schafer A, Chieffo A, Lansky A, Hall S, Arany Z, et al. Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clin Cardiol 2019;42:974–981. https://doi.org/10.1002/clc.23249
Olson TL, O'Neil ER, Ramanathan K, Lorusso R, MacLaren G, Anders MM. Extracorporeal membrane oxygenation in peripartum cardiomyopathy: A review of the ELSO registry. Int J Cardiol 2020;311:71–76. https://doi.org/10.1016/j.ijcard.2020.03.006
Sieweke JT, Pfeffer TJ, Berliner D, Konig T, Hallbaum M, Napp LC, et al. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2020;9:173–182. https://doi.org/10.1177/2048872618777876
Joshi AA, Lerman JB, Sajja AP, Dahiya G, Gokhale AV, Dey AK, et al. Sex‐based differences in left ventricular assist device utilization: Insights from the Nationwide Inpatient Sample 2004 to 2016. Circ Heart Fail 2019;12:e006082. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006082
Radhoe SP, Jakus N, Veenis JF, Timmermans P, Pouleur AC, Rubis P, et al. Sex‐related differences in left ventricular assist device utilization and outcomes: Results from the PCHF‐VAD registry. ESC Heart Fail 2023;10:1054–1065. https://doi.org/10.1002/ehf2.14261
Magnussen C, Bernhardt AM, Ojeda FM, Wagner FM, Gummert J, de By T, et al. Gender differences and outcomes in left ventricular assist device support: The European Registry for Patients with Mechanical Circulatory Support. J Heart Lung Transplant 2018;37:61–70. https://doi.org/10.1016/j.healun.2017.06.016
Berliner D, Li T, Mariani S, Hamdan R, Hanke J, Konig T, et al. Clinical characteristics and long‐term outcomes in patients with peripartum cardiomyopathy (PPCM) receiving left ventricular assist devices (LVAD). Artif Organs 2023;47:417–424. https://doi.org/10.1111/aor.14406
Garcia‐Cosio MD, Gonzalez‐Vilchez F, Lopez‐Vilella R, Barge‐Caballero E, Gomez Bueno M, Martinez‐Selles M, et al. Influence of gender in advanced heart failure therapies and outcome following transplantation. Front Cardiovasc Med 2021;8:630113. https://doi.org/10.3389/fcvm.2021.630113
Lavie CJ, Arena R, Franklin BA. Cardiac rehabilitation and healthy life‐style interventions: Rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol 2016;67:13–15. https://doi.org/10.1016/j.jacc.2015.09.103
Samayoa L, Grace SL, Gravely S, Scott LB, Marzolini S, Colella TJ. Sex differences in cardiac rehabilitation enrollment: A meta‐analysis. Can J Cardiol 2014;30:793–800. https://doi.org/10.1016/j.cjca.2013.11.007
Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med 2021;385:203–216. https://doi.org/10.1056/NEJMoa2026141
Supervia M, Medina‐Inojosa JR, Yeung C, Lopez‐Jimenez F, Squires RW, Perez‐Terzic CM, et al. Cardiac rehabilitation for women: A systematic review of barriers and solutions. Mayo Clin Proc 2017;92:P565–P577. https://doi.org/10.1016/j.mayocp.2017.01.002
Colella TJ, Gravely S, Marzolini S, Grace SL, Francis JA, Oh P, et al. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta‐analysis. Eur J Prev Cardiol 2015;22:423–441. https://doi.org/10.1177/2047487314520783
Marzolini S, Brooks D, Oh PI. Sex differences in completion of a 12‐month cardiac rehabilitation programme: An analysis of 5922 women and men. Eur J Cardiovasc Prev Rehabil 2008;15:698–703. https://doi.org/10.1097/HJR.0b013e32830c1ce3
Oosenbrug E, Marinho RP, Zhang J, Marzolini S, Colella TJ, Pakosh M, et al. Sex differences in cardiac rehabilitation adherence: A meta‐analysis. Can J Cardiol 2016;32:1316–1324. https://doi.org/10.1016/j.cjca.2016.01.036